3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Leukemia, Myeloid, Acute
12
Myelodysplastic Syndromes
5
Leukemia, Myelomonocytic, Chronic
3
Leukemia, Biphenotypic, Acute
2
Triple Negative Breast Neoplasms
1
Systemic Mastocytosis With an Associated Hematologic Neoplasm
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Neurofibrosarcoma
1
Neuroendocrine Tumors
1
Neoplasms
1
Myeloproliferative Disorders
1
Melanoma
1
Leukemia, Myeloid, Chronic-Phase
1
Cytopenia
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Breast Neoplasms
1
BRCA1 Mutation
1
Anemia, Refractory, with Excess of Blasts
1
Allogeneic Stem Cell Transplantation
1
Accelerated Phase Myeloproliferative Neoplasm
1
Interventions
lutetium Lu 177 dotatate
29
Everolimus
19
Temozolomide
11
gallium Ga 68 dotatate
10
Nivolumab
10
Magnetic Resonance Spectroscopy
10
Capecitabine
9
pembrolizumab
8
lanreotide
8
Positron Emission Tomography Computed Tomography
8
cabozantinib
7
3-Iodobenzylguanidine
7
177Lu-octreotide, DOTA(0)-Tyr(3)-
7
Somatostatin
6
90Y-octreotide, DOTA-Tyr(3)-
6
telotristat ethyl
5
lenvatinib
5
Octreotide
5
Lutetium-177
5
Ga(III)-DOTATOC
5
Fluorodeoxyglucose F18
5
Carboplatin
5
avelumab
4
Positron-Emission Tomography
4
Ipilimumab
4
Bevacizumab
4
surufatinib
3
pasireotide
3
fluorodopa F 18
3
copper dotatate CU-64
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neuroendocrine Tumors
×
decitabine and cedazuridine drug combination
×
Clear all
NCT05178693
2025-11-24
LANTana
Imperial College London
Phase 1
Recruiting
27 enrolled